BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

MORNING LOWS IN THE 50S AND 60S WARMING UP NICELY ON THURSDAY AN The College Board experienced a glitch that impacted SAT test administrations nationwide today, including sessions at Martin County ...

This rating is the official handicap rating and is assigned to a horse by racing bodies based on the merits of its previous racing performances, with a greater emphasis on recent form.

The cervical examination on admission was 1 cm dilated, 50% effaced, medium consistency and posterior, −3 station, vertex presentation ... anesthesiologist—H.L. sat up and began spontaneous ...

Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...